AstraZeneca immunotherapy combo flunks another lung cancer study - MedCity News

AstraZeneca immunotherapy combo flunks another lung cancer study  MedCity News

The company said Wednesday that the pairing of PD-L1 inhibitor Imfinzi and CTLA-4 inhibitor tremelimumab did not prolong overall survival in previously ...



Comments

Popular posts from this blog

A Review of the Etiology and Epidemiology of Bladder Cancer: All ...

Oncology: The disease, dynamics & challenges of market research

Division of Continuing Professional Development